Xbots Robotics

X-Biotix Therapeutics is a biotechnology company focused on the discovery and development of novel small-molecule antibiotics to combat the global threat of multi-drug resistant (MDR) Gram-negative pathogens. Spun out of X-Chem, the company leverages the proprietary DNA-Encoded X-Chem (DEX) platform to screen ultra-large chemical libraries for scaffolds with inhibitory activity against essential bacterial pathways. X-Biotix employs a multi-target strategy, identifying candidates that target critical biological mechanisms such as cell envelope biosynthesis to defeat known resistance and efflux mechanisms. The company maintains a foundational research collaboration with Harvard Medical School to validate novel antibiotic targets and advance its pre-clinical pipeline.